Thio Chloe L
Johns Hopkins University, Baltimore, MD, USA.
Antivir Ther. 2010;15(3 Pt B):487-91. doi: 10.3851/IMP1553.
Several of the nucleoside/nucleotide analogues used to treat HIV also inhibit HBV replication, with lamivudine being the oldest of this group. Thus, prior to licensing of tenofovir, many HIV-HBV-coinfected individuals received lamivudine as the only drug active against HBV as part of an anti-HIV regimen, which set the stage for the emergence of drug-resistant HBV. In coinfected persons, lamivudine-resistant HBV develops more rapidly than in HBV-monoinfected persons, but it is not known if this is true for the newer agents. Owing to overlapping reading frames of the HBV polymerase and surface antigens, drug-resistant changes in HBV Pol can lead to mutations in the envelope. This review will discuss studies of drug-resistant HBV in HIV-infected persons including drug-resistant mutations that have been identified and clinical sequelae of these mutations.
几种用于治疗HIV的核苷/核苷酸类似物也能抑制HBV复制，拉米夫定是这类药物中最早使用的。因此，在替诺福韦获批之前，许多HIV-HBV合并感染的个体将拉米夫定作为抗HIV治疗方案中唯一一种对HBV有效的药物，这为耐药性HBV的出现埋下了伏笔。在合并感染的患者中，拉米夫定耐药性HBV的出现比单纯HBV感染患者更快，但尚不清楚新型药物是否也是如此。由于HBV聚合酶和表面抗原的阅读框重叠，HBV Pol中的耐药性变化可导致包膜发生突变。本综述将讨论HIV感染者中耐药性HBV的研究，包括已鉴定出的耐药性突变以及这些突变的临床后果。
